Similarly, 2 years after treatment, CD20+ cells were reduced in the CSF from ATZ-treated compared to untreated RR-MS patients, with a predominant treatment effect in the CD20+ T compared to the CD20+ B cell pool [13]. The gene discussed is MS4A1; the disease is myeloid sarcoma.